15-min delayed · Jul 28, 3:45 PM ET · Get real-time quotes →
The Quantellect read.Of the 4 firms covering Myriad Genetics Inc, 1 rate it Buy or better, 3 sit at Hold, and 0 rate it Sell or worse, a moderate buy consensus. Targets span $5.50 to $8.50, a moderate spread. The average target of $6.50 sits 22% above the current $5.33. The rating mix has stayed broadly stable, with Buy-side ratings easing from 3 to 1 over recent months. On the fundamentals, the Street sees consensus EPS building from about $0.07 next quarter toward $0.15 the year after.Descriptive synthesis of third-party analyst data, not a Quantellect rating or recommendation.
ANALYST CONSENSUS4 ratings
Moderate Buy
Strong Buy00%
Buy125%
Hold375%
Sell00%
Strong Sell00%
Based on 4 analysts giving stock ratings to Myriad Genetics Inc.
As of Jul, 1 of 4 firms rate MYGN a Buy (3 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
MYGN EPS & revenue forecast
EPS · NEXT QUARTER
$0.07
Range $0.00 – $0.10 · 9 analysts
Next period, 9 analysts expect Myriad Genetics Inc to earn $0.07 a share (range $0.00 – $0.10), versus $0.00 a year earlier. Full-year consensus is $0.05, growing to $0.15 the year after.
REVENUE · NEXT QUARTER
$224.8M
Range $219.3M – $230.4M · 9 analysts · +9% YoY
Revenue is expected to reach $224.8M (range $219.3M – $230.4M), +9.3% year-over-year. Full-year consensus is $863.6M, rising to $915.8M next year.
Top analysts covering Myriad Genetics Inc
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on MYGN.
#1
SJ
Sung Ji Nam
Scotiabank · Rank #196
Hold
$6.00+12.7% to target
Overall win rate
45%
+ Follow
#2
Matthew Sykes
Goldman Sachs · Rank #226
Buy
$8.00+50.2% to target
Overall win rate
37%
+ Follow
#3
LL
Lu Li
UBS
Hold
$6.00+12.7% to target
Coverage
—
+ Follow
#4
Brandon Couillard
Wells Fargo
Hold
$5.50+3.3% to target
Coverage
—
+ Follow
#5
Andrew Cooper
Raymond James
Buy
$8.00+50.2% to target
Coverage
—
+ Follow
MYGN stock forecast FAQ
What is MYGN's average 12-month price target?+
The 4 analysts with a live target average $6.50 for Myriad Genetics Inc over the next 12 months, ranging from a $8.50 high to a $5.50 low.
Is MYGN stock a Buy, Sell or Hold right now?+
The current consensus is Moderate Buy. Of the 4 analyst ratings, 1 are Buy or Strong Buy, 3 are Hold, and 0 are Sell or Strong Sell.
What are the highest and lowest price targets for MYGN?+
The Street-high target is $8.50 (Piper Sandler), and the Street-low is $5.50 (Wells Fargo). The average of all 4 active targets is $6.50.
How many Wall Street analysts cover MYGN?+
4 analysts have an active rating on Myriad Genetics Inc, and 4 firms carry a live 12-month price target.
Who is the most accurate analyst covering MYGN?+
Among analysts who currently cover MYGN, Sung Ji Nam of Scotiabank has the strongest overall Quantellect track record (Rank #196). Their current call is Hold with a $6.00 target.
What is Myriad Genetics Inc's projected EPS for next quarter?+
The consensus estimate is $0.07 per share (range $0.00 – $0.10) across 9 analysts. Full-year EPS is projected at $0.05, rising to $0.15 the following year.
How much revenue is Myriad Genetics Inc expected to report next quarter?+
Consensus revenue is $224.8M (range $219.3M – $230.4M). Full-year revenue is projected at $863.6M, growing to $915.8M next year.
Have analysts been upgrading or downgrading MYGN lately?+
As of Jul, 1 of 4 firms rate MYGN a Buy (3 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their MYGN calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.
